Infiltrating Bladder Urothelial Carcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive transitional cell carcinoma that arises from the urinary bladder urothelium. 
Infiltrating bladder urothelial carcinomas most frequently harbor alterations in TP53, CDKN2A, KRAS, KMT2D, and KDM6A .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, TP53 Exon 7 Mutation, and TP53 Codon 245 Missense are the most common alterations in infiltrating bladder urothelial carcinoma .
There are 7 clinical trials for infiltrating bladder urothelial carcinoma, of which 7 are open and 0 are completed or closed. Of the trials that contain infiltrating bladder urothelial carcinoma as an inclusion criterion, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).
Circulating and PD-L1 are the most frequent gene inclusion criteria for infiltrating bladder urothelial carcinoma clinical trials .
Nivolumab, cpx-pom, and atezolizumab are the most common interventions in infiltrating bladder urothelial carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.